ReviewFrontiers in immunology2018
Long Pentraxin-3 Modulates the Angiogenic Activity of Fibroblast Growth Factor-2.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Pentraxin 3 levels in polycystic ovary syndrome: a meta-analysis.Journal of ovarian research · 2026Pooled it
- Pentraxin 3 is more accurate than C-reactive protein for Takayasu arteritis activity assessment: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Growth factor applications and clinical translation: advances and challenges.Annals of medicine · 2026Review
- Dermal Microvascular Responses of Human Induced Pluripotent Stem Cell-Derived Skin Organoids to Inflammation and Injury.The American journal of pathology · 2026Article
- Pentraxin 3 ameliorates glucocorticoid-induced osteonecrosis of the femoral head via TLR4/NF-κB/FGF21 signaling axis.Communications biology · 2025Article
- What role do miRNAs play in the injured heart of the infertile female?Biochemistry and biophysics reports · 2025Review
- MALAT1 as a molecular driver of tumor progression, immune evasion, and resistance to therapy.Molecular cancer · 2025Review
- Evaluating pentraxin 3 as a diagnostic biomarker for diabetic retinopathy: a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2025Review
- Influence of Hypoxia on a Biomaterial Model of the Bone Marrow Perivascular Niche.Advanced healthcare materials · 2025Article
- Low-temperature cold plasma promotes wound healing by inhibiting skin inflammation and improving skin microbiome.Frontiers in bioengineering and biotechnology · 2025Article
- Antiangiogenic Potential of an Olive Oil Extract: Insights from a Proteomic Study.Journal of agricultural and food chemistry · 2024Article
- The construction of a microenvironment with the vascular network by co-culturing fibroblasts and endothelial cells.Regenerative therapy · 2024Article
- Review
- The underlying mechanisms of FGF2 in carotid atherosclerotic plaque development revealed by bioinformatics analysis.Archives of medical science : AMS · 2024Article
- The Role of Pentraxin 3 in Gastrointestinal Cancers.Cancers · 2023Review
- Role of long pentraxin PTX3 in cancer.Clinical and experimental medicine · 2023Review
- Article
- GRP78 promotes the osteogenic and angiogenic response in periodontal ligament stem cells.European cells & materials · 2023Article
- PARP Inhibitor Inhibits the Vasculogenic Mimicry through a NF-κB-PTX3 Axis Signaling in Breast Cancer Cells.International journal of molecular sciences · 2022Article
- The natural FGF-trap long pentraxin 3 inhibits lymphangiogenesis and lymphatic dissemination.Experimental hematology & oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis, the process of new blood vessel formation from pre-existing ones, plays a key role in various physiological and pathological conditions. Alteration of the angiogenic balance, consequent to the deranged production of angiogenic growth factors and/or natural angiogenic inhibitors, is responsible for angiogenesis-dependent diseases, including cancer. Fibroblast growth factor-2 (FGF2) represents the prototypic member of the FGF family, able to induce a complex "angiogenic phenotype" in endothelial cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.